(Total Views: 770)
Posted On: 05/03/2020 6:28:39 AM
Post# of 148935
Cytodyn found the "Egg of Columbus" and some basher, shorter and Big Pharma would like to take this "miracle drug" for less than it is worth, out of our hands!
The German Forum as well IHub and Yahoo is full of BS Poster paid by BP, i guess why ??
I found articles, really a interesting read & might confirms the rigged boards:
Novartis owns 33% of Roche:
https://translate.google.com/translate?hl=de&...bt-1502144
How Roche and Novartis are at the forefront of the pharmaceutical industry.
The US company Pfizer has long led the pharmaceutical industry. But now the Swiss pharmaceutical giants Roche and Novartis are pulling past him.
https://translate.google.com/translate?hl=de&...pOprBC-ap3
Well, let's see which of the many BP candidates starts the auction of a partnership!
"LET THE GAMES BEGIN!"
IMO
The German Forum as well IHub and Yahoo is full of BS Poster paid by BP, i guess why ??
I found articles, really a interesting read & might confirms the rigged boards:
Novartis owns 33% of Roche:
https://translate.google.com/translate?hl=de&...bt-1502144
How Roche and Novartis are at the forefront of the pharmaceutical industry.
The US company Pfizer has long led the pharmaceutical industry. But now the Swiss pharmaceutical giants Roche and Novartis are pulling past him.
https://translate.google.com/translate?hl=de&...pOprBC-ap3
Quote:
Successes in oncology But there are also certain parallels: Both companies recognized the potential of new, targeted cancer drugs at a relatively early stage and thus conquered the two leading positions in the booming oncology business over the past decade. They invest in experimental concepts and technologies earlier than many of their competitors. Novartis, for example, is one of the pioneers in the field of novel Car T cell therapies for cancer. With its subsidiary Genentech, Roche has paved the way for the use of antibodies in cancer therapy and is now investing heavily in novel data-based concepts for drug development. Both Roche and Novartis are now involved in gene therapy. Both groups were by no means inactive regarding takeovers. Novartis in particular has long pursued an elaborate but ultimately unsuccessful diversification strategy, including a number of acquisitions in the generics sector, diagnostics companies and the large takeover of the ophthalmology specialist Alcon.
Well, let's see which of the many BP candidates starts the auction of a partnership!
"LET THE GAMES BEGIN!"
IMO
(1)
(0)
Scroll down for more posts ▼